Integrated Analysis Identifies a TRPM4-Related Sodium Overload Signature with Prognostic Value and Experimentally Validates RNPEPL1 in Lung Adenocarcinoma. [PDF]
Cancers (Basel)Xia W +5 more
europepmc +1 more source
Targeting ferroptosis in gefitinib-resistant HCC827 NSCLC cells using erastin. [PDF]
Am J Cancer ResNam AY +5 more
europepmc +1 more source
Integrating clinical outcomes with molecular simulations to guide the selection of non-classical EGFR-TKIs: A comprehensive analysis and development of treatment strategies. [PDF]
Exp Ther MedWei F, Niu N, Li C, Gao G, Li N, Wang Y.
europepmc +1 more source
Evaluation of Itraconazole as a repurposed small molecule inhibitor of EMT in breast cancer: a molecular docking and dynamics study. [PDF]
J Mol ModelGayam PKR, Kulkarni AM, Aranjani JM.
europepmc +1 more source
Mycoplasma infection drives EGFR-TKI resistance through convergent transcriptomic reprogramming in non-small cell lung cancer. [PDF]
iScienceWang B +6 more
europepmc +1 more source
Editor's Note: Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. [PDF]
J Natl Cancer Insteuropepmc +1 more source
Related searches:
Gefitinib is an orally active selective inhibitor epidermal growth factor receptor (EGFR). The large randomised phase III IPASS study (gefitinib 250 mg, daily vs carboplatin and paclitaxel) showed a beneficial effect on progression-free survival (PFS) and quality of life in selected patient populations under the treatment with gefitinib (HR for TKI 0 ...
Rawluk, Justyna, Waller, Cornelius
+9 more sources
Reactions Weekly, 2016 Gefitinib is a small molecule that specifically inhibits the tyrosine kinase (TK) activity of the epidermal growth factor receptor (EGFR) type 1 by interfering with the adenosine triphosphate (ATP) binding site.
Una-Cidon, E +3 more
core +5 more sources
Gefitinib (Iressa®) is a selective inhibitor of epidermal growth factor, a growth factor that plays a pivotal role in the control of cell growth, apoptosis, and angiogenesis. Gefitinib is clinically used for the treatment of chemoresistant non-small cell lung cancer patients.
A F M Motiur, Rahman +2 more
+5 more sources
Gefitinib (ZD1839) is an orally active selective inhibitor of epidermal growth factor receptor tyrosine kinase, an enzyme that regulates intracellular signalling pathways implicated in the proliferation and survival of cancer cells. In human non-small cell lung cancer (NSCLC) cell lines and xenografts, gefitinib dose-dependently inhibited cellular ...
Christine R, Culy, Diana, Faulds
openaire +2 more sources